Generally, therapeutic decisions are based on tumour histology and receptor status: ER (Estrogen Receptor), PR (Progesterone Receptor) and ERBB2, also known as HER2 (Human Epidermal Growth Factor Receptor 2), in tumour tissue biopsies. The gene discussed is ESR1; the disease is neoplasm.